NASDAQ:CING

Cingulate Stock Insider Trading

Healthcare > Biotechnology

Buy CING

*Your capital is at risk

$4.83

-0.110 (-2.23%)

At Close: Jun 23, 2026

Cingulate Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.98. In total, the insiders bought 2.28M and sold 14.73K CING shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.98
● Buy	2.28M shares
● Sell	14.73K shares
93% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Mar 09, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 99.98. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 31, 2026 Buy	Stock Option (right to Buy) A-Award	Silva Raul R. EVP And Cso	Officer	3 422 Value: $21.3K
Mar 09, 2026 Buy	Stock Option (right to Buy) A-Award	Hargroves Thomas Jeffrey Director	Director	15 000 Value: $102.8K
Mar 09, 2026 Buy	Common Stock A-Award	Silva Raul R. EVP And Cso	Officer	4 526 Value: $31.0K
Mar 09, 2026 Sell	Common Stock F-InKind	Silva Raul R. EVP And Cso	Officer	1 828 Value: $0
Mar 09, 2026 Buy	Common Stock A-Award	Schaffer Shane J. Chief Executive Officer	CEO / President	6 862 Value: $47.0K
Mar 09, 2026 Sell	Common Stock F-InKind	Schaffer Shane J. Chief Executive Officer	CEO / President	2 959 Value: $0
Mar 09, 2026 Buy	Common Stock A-Award	Callahan Jennifer L. EVP And CFO	C-Suite Officer	15 329 Value: $105.0K
Mar 09, 2026 Sell	Common Stock F-InKind	Callahan Jennifer L. EVP And CFO	C-Suite Officer	6 427 Value: $0
Mar 09, 2026 Buy	Common Stock A-Award	Patel Nilay Dahyabhai EVP, Clo And Cco	Officer	5 475 Value: $37.5K
Mar 09, 2026 Sell	Common Stock F-InKind	Patel Nilay Dahyabhai EVP, Clo And Cco	Officer	2 086 Value: $0
Mar 09, 2026 Buy	Common Stock A-Award	Brams Matthew EVP And Chief Medical Officer	Officer	4 526 Value: $31.0K
Mar 09, 2026 Sell	Common Stock F-InKind	Brams Matthew EVP And Chief Medical Officer	Officer	1 025 Value: $0
Feb 13, 2026 Buy	Common Stock	Hargroves Thomas Jeffrey Director	Director	0 Value: $0
Feb 13, 2026 Buy	Common Stock P-Purchase	Hargroves Thomas Jeffrey Director	Director	97 276 Value: $490.3K
Feb 13, 2026 Buy	Warrant to Purchase Common Stock P-Purchase	Hargroves Thomas Jeffrey Director	Director	77 821 Value: $392.2K
Feb 06, 2026 Buy	Common Stock P-Purchase	Schaffer Shane J. Chief Executive Officer	CEO / President	6 809 Value: $34.3K
Feb 06, 2026 Buy	Warrant to Purchase Common Stock P-Purchase	Callahan Jennifer L. SVP And CFO	C-Suite Officer	3 891 Value: $19.6K
Feb 06, 2026 Buy	Common Stock P-Purchase	Callahan Jennifer L. SVP And CFO	C-Suite Officer	4 864 Value: $24.5K
Feb 06, 2026 Buy	Warrant to Purchase Common Stock P-Purchase	Werth Peter J. Director	Director	15 564 Value: $78.4K
Feb 06, 2026 Buy	Common Stock P-Purchase	Werth Peter J. Director	Director	19 455 Value: $98.1K
Feb 06, 2026 Buy	Warrant to Purchase Common Stock P-Purchase	Schaffer Shane J. Chief Executive Officer	CEO / President	5 447 Value: $27.5K
Feb 06, 2026 Buy	Common Stock P-Purchase	Brams Matthew EVP And Chief Medical Officer	Officer	1 946 Value: $10K
Feb 06, 2026 Buy	Warrant to Purchase Common Stock P-Purchase	Brams Matthew EVP And Chief Medical Officer	Officer	1 556 Value: $8K
Dec 31, 2025 Buy	Stock Option (right to Buy) A-Award	Silva Raul R. EVP And Cso	Officer	6 625 Value: $28.8K
Nov 03, 2025 Buy	Stock Option (right to Buy) A-Award	Downey Bryan Wade Chief Commercial Officer	Officer	30 000 Value: $114.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CINGULATE INC.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety diso...

Read Full Profile Here